Treatment of parkinson's disease

Journal of Clinical Neuroscience

Volumn 7, Issue 6, 2000, Pages 484-494

  Hely, Mariese A ^a   Fung, Victor S C ^a   Morris, John G L ^a  

^a WESTMEAD HOSPITAL   (Australia)

Author keywords

Parkinson's disease; Surgery; Treatment

Indexed keywords

AMANTADINE; APOMORPHINE; BENZATROPINE; BIPERIDEN; BROMOCRIPTINE; CABERGOLINE; CATECHOL METHYLTRANSFERASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; LEVODOPA; PERGOLIDE; PRAMIPEXOLE; PROCYCLIDINE; ROPINIROLE; SELEGILINE; TOLCAPONE;

BRAIN DEPTH STIMULATION; DOSE RESPONSE; DRUG INDUCED DISEASE; DYSKINESIA; GLOBUS PALLIDUS; HUMAN; NEUROPROTECTION; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SUBTHALAMIC NUCLEUS; THALAMUS;

EID: 0033724775     PISSN: 09675868     EISSN: None     Source Type: Journal    
DOI: 10.1054/jocn.2000.0766     Document Type: Review

References (121)

1. Does levodopa therapy delay death in Parkinson's disease? A review of the evidence
2. The Sydney multicentre study of Parkinson's disease: Progression and mortality at 10 years
3. Effect of L-dopa on course of Parkinson's disease
4. Levodopa. Is Toxicity a myth?
5. The Sydney Multicentre Study of Parkinson's disease: A randomised, prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa
6. Does levodopa aggravate Parkinson's disease?
7. The occurrence of motor fluctuations in parkinsonian patients treated long term with levodopa: Role of early treatment and disease progression
8. The role of pulsatile versus continuous dopamine receptor stimulation for functional recovery in Parkinson's disease
9. Does long-term aggravation of Parkinson's disease result from nondopaminergic lesions?
10. Gila protect fetal midbrain dopamine neurons in culture from L-DOPA toxicity throuh multiple mechanisms
11. Is levodopa toxic?
12. Multicentre study of Parkinson Mortality with early versus later dopa treatment
13. Mortality associated with early and late levodopa therapy initiation in Parkinson's disease
14. Timely levodopa (LD) administration prolongs survival in Parkinson's disease
15. Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with mderate nigrostriatal lesions
16. Welcome news about levodopa, but uncertainty remains
17. Does selegiline delay progression of Parkinson's disease? A critical re-evaluation of the DATATOP study
18. United Kingdom: Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease
19. Selegiline and mortality in Parkinson's disease
20. Mortality in DATATOP: A multicenter trial in early Parkinson's disease
21. Do dopamine agonists provide Neuroprotection?
22. The effect of deprenyl and levodopa on the progression of Parkinson's disease
23. Dopamine/glutamate interactions in Parkinson's disease
24. Subthalamic nucleus-mediated excitotoxicity in Parkinson's disease: A target for Neuroprotection
25. Selegiline: Current perspectives on issues related to Neuroprotection and mortality
26. Young-onset Parkinson's disease revisited-clinical features, natural history, and mortality
27. Parkinsonism: Onset, progression and mortality
28. Comparison of immediaterelease and controlled-release carbidopa/levodopa in Parkinson's disease: A multicentre 5 year study
29. Malignant melanoma and levodopa: Is there a relationship? Two new cases and a review of the literature
30. Levodopa, melanoma, and Parkinson's disease
31. Dopamine agonists
32. A randomised control study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: A five year follow up
33. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial
34. Ropinirole reduces risk of dyskinesia when used in early Parkinson's disease
35. United Kingdom: Comparison of therapeutic effects of levodopa, levodopa and selegiline and bromocriptine in patients with early, mild Parkinson's disease: Three year interim report
36. Long-term bromocriptine treatment of de novo patients with Parkinson's disease. A seven-year follow-up study
37. Ropinirole in the treatment of early Parkinson's disease: A 6-month interim report of a 5-year levodopa-controlled study
38. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease
39. A comparison of ropinirole and bromocriptine in the treatment of early Parkinson's disease for 3 years
40. A three and a half year experience with pramipexole (PMPX) monotherapy in patients with early Parkinson's disease
41. A crossover, controlled study comparing pergolide with bromocriptine as an adjunct to levodopa for the treatment of Parkinson's disease
42. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease
43. Double-blind comparison of cabergoline and bromocriptine in Parkinson's disease patients with motor fluctuations
44. Falling asleep at the wheel: Motor vehicle mishaps in persons taking pramipexole and ropinirole
45. Chronic agonist therapy for Parkinson's disease: A five-year study of bromocriptine and pergolide
46. Switching dopamine agonists in advanced Parkinson's disease. Is rapid titration preferable to slow?
47. Treatment of Parkinson's disease
48. An Australian multicentre open label study of pergolide as an adjunct to levodopa in Parkinson's disease
49. A multicentre trial of ropinirole as adjunct treatment for Parkinson's disease
50. A multicentre double-blind placebo controlled trial of pergolide as an adjunct to sinemet in Parkinson's disease
51. COMT inhibition: A new treatment strategy for Parkinson's disease
52. Tolcapone improves motor function in Parkinsonian patients with 'wearing-off' phenomenon: A double-blind, placebo-controlled, multicentre trial
53. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations
54. Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients
55. Adverse Drug Reactions Advisory Committee. Cisapride and cardiac arrhythmias
56. Effect of subcutaneous administration of levodopa ethyl ester, a soluble prodrug of levodopa, on dopamine metabolism in rodent striatum: Implication for treatment of Parkinson's disease
57. Stride length regulation in Parkinson's disease. Normalization strategies and underlying mechanisms
58. Subcutaneous apomorphine in Parkinson's disease: Response to chronic treatment for up to five years
59. Subcutaneous apomorphine in the treatment of Parkinson's disease
60. Continuous subcutaneous apomorphine infusions for fluctuating Parkinson's disease. Long-term follow-up in 18 patients
61. Continuous subcutaneous waking day apomorphine in the long-term treatment of levodopa induced interdose dyskinesias in Parkinson's disease
62. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease
63. Swallowing abnormalities and their response to treatment in Parkinson's disease
64. Depression in Parkinson's disease. Impediments to recognition and treatment options
65. Movement disorders associated with the serotonin selective reuptake inhibitors
66. Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease
67. Sertraline for the treatment of depression in Parkinson's disease
68. Clozapine use in Parkinson's disease: A retrospective analysis of a large multicentered clinical experience
69. Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease
70. Risperidone in Parkinson's disease
71. An estimate of the incidence of dementia in idiopathic Parkinson's disease
72. A longitudinal study of Parkinson's disease: Clinical and neuropsychological correlates of dementia
73. Attempting to predict response to pallidotomy
74. Preoperative indicators of clinical outcome following bilateral subthalamic nucleus stimulation for the treatment of Parkinson's disease
75. Treatment of advanced Parkinson's disease by posterior GPi pallidotomy: 1-year results of a pilot study
76. Stereotactic ventral pallidotomy for Parkinson's disease
77. A study of medial pallidotomy for Parkinson's disease: Clinical outcome, MRI location and complications
78. Neuropsychological, neurological and functional outcome following pallidotomy for Parkinson's disease. A consecutive series of eight simultaneous bilateral and twelve unilateral procedures
79. Stereotactic pallidotomy for the treatment of Parkinson's disease. Efficacy and adverse effects at 6 months in 26 patients
80. Posteroventral medial pallidotomy in advanced Parkinson's disease
81. Surgical treatment of Parkinson's disease
82. Posteroventral medial pallidotomy in advanced Parkinson's disease
83. Bilateral subthalamic or pallidal stimulation for Parkinson's disease affects neither memory nor executive functions: A consecutive of series of 62 patients
84. Neuropsychological consequences of posteroventral pallidotomy for the treatment of Parkinson's disease
85. Cognitive sequelae of unilateral posteroventral pallidotomy
86. Cognitive outcome after unilateral pallidal stimulation in Parkinson's disease
87. Current controversies in pallidal surgery
88. Stereotactic pallidotomy in the treatment of Parkinson disease: An expert opinion
89. Pallidotomy for Parkinson's disease
90. Voluntary movement after pallidotomy in severe Parkinson's disease
91. The effects of posteroventral pallidotomy on the preparation and execution of voluntary hand and arm movements in Parkinson's disease
92. A prospective study of posteroventral pallidotomy in the treatment of Parkinson's disease
93. Usefulness of pallidotomy in advanced Parkinson's disease
94. Relationship of lesion location to clinical outcome following microelectrode-guided pallidotomy for Parkinson's disease
95. Opposite motor effects of pallidal stimulation in Parkinson's disease
96. Deep brain stimulation in Parkinson's disease: Opposite effects of stimulation in the pallidum
97. Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease
98. Double-blind evaluation of subthalamic nucleus deep brain stimulation in advanced Parkinson's disease
99. The effect of subthalamic nucleus stimulation on levodopa-induced dyskinesias in patients with Parkinson's disease
100. Bilateral contemporaneous posteroventral pallidotomy for the treatment of Parkinson's disease: Neuropsychological and neurological side effects. Report of four cases and review of the literature
101. Evolution of a surgical technique for posteroventral pallidotomy using CT/MRI fusion and intraoperative macrostimulation
102. Bilateral dorsolateral subthalamotomy for advanced Parkinson's disease
103. The role of the subthalamic nucleus in the origin of hemiballism and parkinsonism: New surgical perspectives
104. High-frequency stimulation of the globus pallidus for the treatment of Parkinson's disease
105. Unilateral pallidal stimulation for Parkinson's disease: Neurobehavioral functioning before and 3 months after electrode implantation
106. Efficiency and safety of bilateral contemporaneous pallidal stimulation (deep brain stimulation) in levodopa-responsive patients with Parkinsons's disease with severe motor fluctuations: A two year follow-up review
107. Pallidal stimulation in Parkinson's disease patients with a prior unilateral pallidotomy
108. Stereotactic surgery and Parkinson's disease
109. Thalamotomy
110. Combined (thalamotomy and stimulation) stereotactic surgery of the VIM thalamic nucleus for bilateral Parkinson disease
111. Long-term suppression of tremor by chronic stimulation of the ventral intermediate thalamic nucleus
112. High-frequency unilateral thalamic stimulation in the treatment of essential and parkinsonian tremor
113. Multicentre European study of thalamic stimulation in parkinsonian and essential tremor
114. Pallidotomy for tremor
115. Treatment of tremor in Parkinson's disease by subthalamic nucleus stimulation
116. Primate models of movement disorders of basal ganglia origin
117. Neurophysiological identification of the subthalamic nucleus in surgery for Parkinson's disease
118. Effects of apomorphine on globus pallidus neurons in parkinsonian patients
119. The current model of basal ganglia organization under scrutiny
120. Basal ganglia and movement disorders: An update
121. Basal ganglia pathophysiology. A critical review